What is the Best Treatment for Children with Vesicoureteral Reflux (VUR)?
Renal Damage Results of Swedish Reflux Trial Reported in The Journal of Urology®
New York, NY, 25 May, 2010 – Children with vesicoureteral reflux (VUR), in which urine flows backwards into the kidneys from the bladder, have been treated in the past with surgery or antibiotic therapy. Although this condition can lead to renal damage, there have been few controlled studies to help determine the most effective treatment of young children. A study, part of the Swedish Reflux Trial, is scheduled for publication in the July 2010 issue of The Journal of Urology.
Investigators from the Pediatric Uro-Nephrologic Center, The Queen Silvia Children’s Hospital, University of Gothenburg, Sweden, led a national study in which 203 children with VUR were followed in a randomized clinical trial (128 girls and 75 boys). One-third received prophylactic antibiotics, one-third received endoscopic intervention and one-third was observed with no treatment.
“Controlled studies are needed to provide an evidence base for treatment in children with VUR,” according to lead investigator Sverker Hansson, MD. “The Swedish Reflux Trial was set up as a RCT to compare long-term antibiotic prophylaxis, endoscopic correction and surveillance as the control group in children with dilating VUR in regard to the febrile UTI rate, and kidney and VUR status at 2 years. Secondary outcomes were complications and the impact of factors such as VUR grade, gender and bladder dysfunction. In the current report we analyzed the progression of renal defects present at entry and the development of new renal damage in the 3 treatment groups.”
The researchers found that the rate of new renal damage in boys was low, with only one boy who received endoscopic treatment and one on surveillance having further damage. In girls the rate was higher (13 or 10%) and there was a significant difference between treatment groups with new damage most common in controls on surveillance. New damage was observed in 19% of girls on surveillance, 12% who received endoscopic treatment and in none on prophylaxis.
There was a strong association between recurrent febrile urinary tract infections (UTI) and new renal damage in girls but recurrent UTIs and new damage were unusual in boys. The febrile UTI rate differed significantly between treatment groups in girls, including a recurrence rate of 57% in the surveillance, 23% in the endoscopic and 19% in the prophylactic groups.
Dr. Hansson and co-investigators state, “An interesting finding was that new damage as well as the progression of previously observed renal uptake defects was only seen in kidneys drained by ureters with dilating VUR with 1 exception. There was no difference in this respect whether VUR was grade III or IV at study entry. Previously unscarred kidneys were as vulnerable to new renal damage as those with uptake defects at entry.”
# # #
Note to Editors
The article is “The Swedish Reflux Trial in Children: IV. Renal Damage” by Per Brandström, Tryggve Nevéus, Rune Sixt, Eira Stokland, Ulf Jodal and Sverker Hansson. It is published online (DOI:10.1016/j.juro.2009.12.021) and will appear in The Journal of Urology, Volume 184 Issue 1 (July 2010) published by Elsevier.
Full text of the article featured above is available upon request. Contact Linda Gruner at 212-633-3923 or email email@example.com to obtain a copy. To schedule an interview with Dr. Sverker Hansson, contact Pia Lundegaard at +46 31 3434662 or email firstname.lastname@example.org.
About The Journal of Urology®
Established in 1917, The Journal of Urology (www.jurology.com) is the official journal of the American Urological Association (www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).